Accéder au contenu
Merck

Ginsenoside Rg3 attenuates cisplatin-induced kidney injury through inhibition of apoptosis and autophagy-inhibited NLRP3.

Journal of biochemical and molecular toxicology (2021-08-24)
Jinghui Zhai, Huan Gao, Shuo Wang, Sixi Zhang, Xiaoyu Qu, Yueming Zhang, Lina Tao, Jingmeng Sun, Yanqing Song, Li Fu
RÉSUMÉ

The NOD-like receptor family pyrin domain-containing (NLRP3) inflammasomes is centrally implicated in cisplatin (CP)-induced kidney injury. Autophagy is critical for inhibiting production of NLRP3 protein that effectively reduces the inflammatory response. Ginsenoside Rg3 (SY), an active component extracted from ginseng, is reported to protect against CP-induced nephrotoxicity. However, the mechanisms underlying renoprotection by SY have not been established to date. Our results indicate that SY attenuated CP-induced apoptosis and damage in vivo and in vitro, as evidenced by increased cell viability, decreased the proportion of late apoptotic cells, elevated mitochondrial membrane potential, and ameliorated histopathological damage of the kidney. SY ameliorated CP-induced human renal tubular (HK-2) cells and kidney injury through upregulation of LC3II/I and beclin-1, inhibition of p62, NLRP3, ASC, caspase-1, and interleukin-1β. However, blockade of autophagy by 3-methyladenine reversed the suppression of SY on NLRP3 inflammasome activation and the protection of SY on HK-2 cells. Our collective results support the utility of SY as a therapeutic agent that effectively protects against CP-induced kidney injury by activating the autophagy-mediated NLRP3 inhibition pathway.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Autophagy Inhibitor, 3-MA, Autophagy Inhibitor, 3-MA, CAS 5142-23-4, is a cell-permeable autophagic sequestration blocker. Acts as an inhibitor of III PI3-Kinase.